Tirzepatide 5 mg Driada Medical

Description

Tirzepatide 5 mg Driada Medical — tirzepatide from Driada Medical at 5 mg. Dual GIP and GLP-1 receptor agonist. Produces larger weight-loss effect than pure GLP-1 agonists in clinical trials.

Key Benefits

• Dual GIP + GLP-1 receptor agonist — broader incretin action than semaglutide
• Clinical data: 15–21% body-weight reduction at therapeutic dose over 72 weeks
• Superior HbA1c reduction vs semaglutide in head-to-head trials
• Weekly SubQ dosing with graduated titration
• Currently the most effective commercial weight-loss pharmacotherapy
• Each unit dosed at 5 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Clinical dosing titration (Mounjaro/Zepbound protocol): weeks 1–4: 2.5 mg/week; weeks 5–8: 5 mg/week; weeks 9–12: 7.5 mg/week; weeks 13–16: 10 mg/week; week 17–20: 12.5 mg/week; week 21+: 15 mg/week maintenance. Slow titration is standard — faster escalation amplifies GI side-effects.

How It Works

First-in-class dual-agonist: activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. The dual-mechanism produces additive effects on insulin secretion, appetite suppression, and adipose-tissue metabolism that single-target GLP-1 agonists don’t match.

Pharmacokinetics

Plasma half-life approximately 5 days. Weekly SubQ dosing (abdomen/thigh/upper arm). Steady-state at 4 weeks. Reconstituted vial stable in fridge for 21 days after first use.

Potential Side Effects

GI side-effects similar to semaglutide (nausea, vomiting, diarrhoea, constipation) but frequency slightly higher due to dual mechanism. Dose-dependent muscle-mass loss requires concurrent resistance training. Pancreatitis rare. Gallbladder events possible at high maintenance dose.

Cycle & Stacking Guide

16–24+ week protocols. Titrate slowly. Resistance training + high-protein diet non-negotiable to preserve lean mass. Post-discontinuation weight rebound documented; long-term maintenance strategy required (gradual taper or weekly micro-dose).

Manufacturer Notes

Driada Medical positions itself at the affordable end of the market while maintaining third-party lab verification. Their vial caps carry a tamper-seal date code.

Storage & Handling

Lyophilised (freeze-dried) form: stable at 2–8 °C in the sealed vial for the duration printed on the label. After reconstitution with bacteriostatic water, store reconstituted solution at 2–8 °C and use within 30 days. Do not freeze reconstituted peptide — ice crystals denature the molecule. Keep out of reach of children. For research and educational purposes only.